Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition

References

• Arteaga CL. EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer Cell. 2006;9:421–423. doi:10.1016/j.ccr.2006.05.014.
   PubMed Web of Science ®Google Scholar
• Jr RR. ErbB/HER protein-tyrosine kinases: structures and small molecule inhibitors. Pharmacol Res. 2014;87:42–59. doi:10.1016/j.phrs.2014.06.001.
   PubMed Web of Science ®Google Scholar
• Jr RR. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74. doi:10.1016/j.phrs.2013.11.002.
   PubMed Web of Science ®Google Scholar
• Dhomen NS, Mariadason J, Tebbutt N, Scott AM. Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncog. 2012;17:31–50.
   PubMedGoogle Scholar
• Reinmuth N, Brandt B, Kunze WP, Junker K, Thomas M, Achatzy R, Scheld HH, Semik M. Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur Respir J. 2000;16:991–996.
   PubMed Web of Science ®Google Scholar
• Gao JW, Zhan P, Qiu XY, Jin JJ, Lv TF, Song Y. Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials. Oncotarget. 2017;8:73258–73270. doi:10.18632/oncotarget.18319.
   PubMedGoogle Scholar
• Kazandjian D, Keegan P, Suzman DL, Pazdur R, Blumenthal GM. Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials. Semin Oncol. 2017;44:3–7. doi:10.1053/j.seminoncol.2017.01.001.
   PubMed Web of Science ®Google Scholar
• Mengoli MC, Barbieri F, Bertolini F, Tiseo M, Rossi G. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: report of two cases and review of the literature. Lung Cancer. 2016;93:55–58. doi:10.1016/j.lungcan.2016.01.002.
   PubMed Web of Science ®Google Scholar
• Piva S, Ganzinelli M, Garassino MC, Caiola E, Farina G, Broggini M, Marabese M. Across the universe of K-RAS mutations in non-small-cell-lung cancer. Curr Pharm Des. 2014;20:3933–3943.
   PubMed Web of Science ®Google Scholar
• Ihle NT, Jr LR, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009;69:143–150. doi:10.1158/0008-5472.CAN-07-6656.
   PubMed Web of Science ®Google Scholar
• Carón RW, Yacoub A, Zhu X, Mitchell C, Han SI, Sasazuki T, Shirasawa S, Hagan MP, Grant S, Dent P. H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent. Mol Cancer Ther. 2005;4:243–255.
   PubMed Web of Science ®Google Scholar
• Carón RW, Yacoub A, Li M, Zhu X, Mitchell C, Hong Y, Hawkins W, Sasazuki T, Shirasawa S, Kozikowski AP, et al. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Mol Cancer Ther. 2005;4:257–270.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Tavallai M, Webb T, Leon D, Chen J, McGuire WP, Poklepovic A, Dent P. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Oncotarget. 2016;7:19620–19630. doi:10.18632/oncotarget.7746.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Poklepovic A, Dent P. NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells. Oncology Signaling. doi:10.1016/j.onsig.2017.07.001.
   Google Scholar
• Cruickshanks N, Roberts JL, Bareford MD, Tavallai M, Poklepovic A, Booth L, Spiegel S, Dent P. Differential regulation of autophagy and cell viability by ceramide species. Cancer Biol Ther. 2015;16:733–742. doi:10.1080/15384047.2015.1026509.
   PubMed Web of Science ®Google Scholar
• Azuma H, Takahara S, Ichimaru N, Wang JD, Itoh Y, Otsuki Y, Morimoto J, Fukui R, Hoshiga M, Ishihara T, et al. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res. 2002;62:1410–1419.
   PubMed Web of Science ®Google Scholar
• Nagahashi M, Hait NC, Maceyka M, Avni D, Takabe K, Milstien S, Spiegel S. Sphingosine-1-phosphate in chronic intestinal inflammation and cancer. Adv Biol Regul. 2014;54:112–120. doi:10.1016/j.jbior.2013.10.001.
   PubMedGoogle Scholar
• Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, Hait NC, Allegood JC, Price MM, Avni D, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013;23:107–120. doi:10.1016/j.ccr.2012.11.013.
   PubMed Web of Science ®Google Scholar
• Nagahashi M, Yamada A, Katsuta E, Aoyagi T, Huang WC, Terracina KP, Hait NC, Allegood JC, Tsuchida J, Yuza K, et al. Targeting the SphK1/S1P/S1PR1 axis that links obesity, chronic inflammation and breast cancer metastasis. Cancer Res. 2018 Jan 19. doi:10.1158/0008-5472.CAN-17-1423.
   PubMedGoogle Scholar
• Booth L, Roberts JL, Tavallai M, Chuckalovcak J, Stringer DK, Koromilas AE, Boone DL, McGuire WP, Poklepovic A, Dent P. [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling. Oncotarget. 2016;7:23608–23632. doi:10.18632/oncotarget.8281.
   PubMedGoogle Scholar
• Booth L, Roberts JL, Poklepovic A, Gordon S, Dent P. PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. Oncotarget. 2017;8:1449–1468. doi:10.18632/oncotarget.13640.
   PubMedGoogle Scholar
• Lima S, Takabe K, Newton J, Saurabh K, Young MM, Leopoldino AM, Hait NC, Roberts JL, Wang HG, Dent P, et al. TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibition. Autophagy. 2018;25:1–50. doi:10.1080/15548627.2018.1429875.
   Google Scholar
• Goodall ML, Fitzwalter BE, Zahedi S, Wu M, Rodriguez D, Mulcahy-Levy JM, Green DR, Morgan M, Cramer SD, Thorburn A. The autophagy machinery controls cell death switching between apoptosis and necroptosis. Dev Cell. 2016;37:337–349. doi:10.1016/j.devcel.2016.04.018.
   PubMed Web of Science ®Google Scholar
• Garcia CA, Wu S. Attributable risk of infection to mTOR inhibitors everolimus and temsirolimus in the treatment of cancer. Cancer Invest. 2016;34:521–530. doi:10.1080/07357907.2016.1242009.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis. Expert Rev Anticancer Ther. 2015;15:847–858. doi:10.1586/14737140.2015.1047350.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Medin J, Couto CA, Mitchell CR. Multiple sclerosis in the real world: A systematic review of fingolimod as a case study. Autoimmun Rev. 2017;16:355–376. doi:10.1016/j.autrev.2017.02.007.
   PubMed Web of Science ®Google Scholar
• Newton J, Hait NC, Maceyka M, Colaco A, Maczis M, Wassif CA, Cougnoux A, Porter FD, Milstien S, Platt N, et al. FTY720/fingolimod increases NPC1 and NPC2 expression and reduces cholesterol and sphingolipid accumulation in Niemann-Pick type C mutant fibroblasts. FASEB J. 2017;31:1719–1730. doi:10.1096/fj.201601041R.
   PubMed Web of Science ®Google Scholar
• Hait NC, Wise LE, Allegood JC, O’Brien M, Avni D, Reeves TM, Knapp PE, Lu J, Luo C, Miles MF, et al. Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nat Neurosci. 2014;17:971–980. doi:10.1038/nn.3728.
   PubMed Web of Science ®Google Scholar
• Hait NC, Avni D, Yamada A, Nagahashi M, Aoyagi T, Aoki H, Dumur CI, Zelenko Z, Gallagher EJ, Leroith D, et al. The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer. Oncogenesis. 2015;4:e156. doi:10.1038/oncsis.2015.16.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Poklepovic A, Dent P. [pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells. Cancer Biol Ther. 2017;18:705–714. doi:10.1080/15384047.2017.1362511.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Poklepovic A, Kirkwood J, Dent P. HDAC inhibitors enhance the immunotherapy response of melanoma cells. Oncotarget. 2017;8:83155–83170. doi:10.18632/oncotarget.17950.
   PubMedGoogle Scholar